AIFD’s new Board of Directors is elected
The 17th Ordinary General Assembly of the Research-Based Pharmaceutical Companies Association (AIFD) is held on February 14th. General Assembly elected the new Board of Directors and Board of Auditors of AIFD for the new term. AbbVie Turkey General Manager Dr. Mete Hüsemoğlu is elected as the Chairman of the AIFD Board of Directors.
The 17th Ordinary General Assembly of the Research-Based Pharmaceutical Companies Association (AIFD) is held on February 14th in Istanbul. General Assembly elected the new Board of Directors and Board of Auditors. Dr. Mete Hüsemoğlu is elected as the Chairman of the Board.
AIFD members of the Board of Directors for the new term are as follows: Ali Cem Öztürk (Sanofi), Avinash Potnis (Novartis), Burak Cem (Novo Nordisk), Jose Daniel Lucas Guerrero (Lilly), Mustafa Cem Açık (Pfizer), Natasa Klicko (Roche), Renan Özyerli (MSD), Selim Giray (GSK), Dr. Mete Hüsemoğlu (AbbVie), Şehram Zayer (Merck) and Uğur Bingöl (İ.E Menarini). The members of the AIFD Board of Auditors, elected by the General Assembly are as follows: Demet Russ (Johnson & Johnson), Muhittin Bilgütay (Bausch + Lomb) and Serkan Barış (AstraZeneca).
At the AIFD General Assembly, the 2019 priorities and initiatives of the association are brought to discussion and priorities and initiatives for 2020 are discussed. Addressing to the General Assembly, Dr. Mete Hüsemoğlu stated that the foundation of AIFD is to “work to improve patients’ access to innovative medicines and treatments in Turkey, providing ethical and transparent business and work environment in the healthcare field, and in line with the vision through a constructive approach, contribute to Turkey’s developing healthcare system and growing economy, in partnership with all stakeholders and to continue to do so in the future.”
“As we always say, patients are at the center of the healthcare system. Being the key stakeholders of the heathcare system, our reason of being is to create value for the patient. In 2020, it will continue to be our priority to keep patients in our focus and improve their access to the best and advanced treatments,” he added.
Mr. Hüsemoğlu concluded his speech by congratulating the Board members served for the past term and stated his firm believe in AIFD continuing to contribute at an increasing pace to the healthcare environment and economy of our country in 2020.